Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.70 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSB | P07858 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16617441 | 0.96 | CTSK (0.72) | CTSKCTSSCTSBKCNH2KMT2A | |
| SCHEMBL16624863 | 0.93 | CTSK (0.72) | CTSKCTSSCTSBKCNH2KMT2A | |
| SCHEMBL16618033 | 0.90 | CTSK (0.64) | CTSKCTSSCTSBKCNH2KMT2A | |
| SCHEMBL16617440 | 0.90 | CTSK (0.64) | CTSKCTSSCTSBKCNH2KMT2A | |
| SCHEMBL16624861 | 0.90 | CTSK (0.74) | CTSKCTSSCTSBKCNH2KMT2A | |
| SCHEMBL16624858 | 0.89 | CTSK (0.72) | CTSKCTSSCTSBKCNH2KMT2A | |
| SCHEMBL16617702 | 0.88 | CTSK (0.74) | CTSKCTSSCTSBKCNH2KMT2A | |
| SCHEMBL16624857 | 0.88 | CTSK (0.71) | CTSKCTSSCTSBKCNH2KMT2A | |
| SCHEMBL16617664 | 0.88 | CTSK (0.75) | CTSKCTSSCTSBKCNH2KMT2A | |
| SCHEMBL16624859 | 0.87 | CTSK (0.69) | CTSKCTSSCTSBKCNH2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458181-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2015054089-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | CTSK 4/4885CTSS 2/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.